A Review of Hemorrhoidal Disease
Pourkarim F and Entezari-Maleki T
Real-World Evidence for Medicare Drug Price Negotiations
Carey C and Maciejewski ML
A Review of Hemorrhoidal Disease
Pata F, Gravante G and Nardo B
The Three O'Clock Patient
Litwin MS
New Standards Set for Sickle Cell Disease Care
Anderer S
Hypertension Among Children Has Increased Significantly
Anderer S
Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Research Summary
Coffee and AFib, Oral PCSK9 Drugs, an HFrEF Polypill, and Vitamin D Post-MI-Highlights From AHA 2025
Abbasi J
Alzheimer Disease Blood Test Cleared for Primary Care, but Questions Remain About Its Use
Rubin R
Ultraprocessed Foods Linked to Signs of Early-Onset Colorectal Cancer in Women
Pant S
Recommendations for Outpatient Care Following Traumatic Brain Injury
Anderer S
WHO Releases First Global Guidelines for Diabetes Management in Pregnancy
Anderer S
From the Other Side of the Bed
Thomson LR
A Review of Hemorrhoidal Disease
La Raja C, Lecchi F and Stuto A
Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial
Lopes RD, Bocchi EA, Echeverría LE, Demacq C, de Barros E Silva PGM, Barbosa LM, Damiani L, Sayyed S, Yoshida LAF, Furtado RHM, Morillo CA, Kevorkian R, Ramires F, Bahit MC, Magaña A, Chávez-Mendoza A, Miguel da Silva AH, Coelho da Silva A, Freitas AF, Romano AA, Parneix A, Segura A, França CCB, Botta CE, de Barros E, Perna ER, Montenegro E, Quiroz Diaz FR, Feitosa-Filho GS, Severini GV, Molina I, Miranda JDSS, Sala J, Kerr Saraiva JF, Carbajales J, Maia LN, Santana Passos LC, Simões MV, Moreira MDCV, Nunes MCP, Hernandes ME, Hominal M, Zarandon RS, Leon de la Fuente R, Aras R, Bazan SGZ, Luiz da Silva T, Madrini V, de Oliveira WA, Saporito WF, Gimpelewicz C, McMurray JJV and
The efficacy and safety of guideline-recommended treatments for heart failure (HF) are uncertain in patients with Chagas disease.
A Review of Hemorrhoidal Disease-Reply
Ashburn JH
Alteplase 4.5 to 24 Hours After Acute Ischemic Stroke
Xie R and Xiao L
Incorrect Values for Baseline Variables in Table 1
Alteplase 4.5 to 24 Hours After Acute Ischemic Stroke
Nakazawa T and Norisue Y
FDA Removes Some Warnings on Menopause Hormone Therapies
Pant S
